Thermo Fisher Scientific Ustekinumab Monoclonal Antibody (5F9)

Applications

• ELISA (ELISA): 0.01–1 µg/mL

Product Specifications

Product Specific Information

Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
The lyophilized product remains stable up to 1 year at −20 °C from date of receipt.
Upon reconstitution, it can be stored for 2–3 weeks at 2–8 °C or for up to 12 months at −20 °C or below.
Avoid repeated freezing and thawing cycles.

Target Information

Ustekinumab is a human IgG1 kappa monoclonal antibody directed against interleukin (IL)-12 and IL-23, cytokines involved in immune and inflammatory responses.
It was generated via recombinant human IL-12 immunization of human Ig transgenic mice.
Ustekinumab acts as a targeted biologic disease-modifying anti-rheumatic drug (bDMARD) used in research related to inflammatory conditions involving IL-12 and IL-23 signaling pathways.
IL-12 and IL-23 are heterodimeric cytokines that mediate immune responses such as natural killer cell activation and CD4+ T-cell differentiation.
They are implicated in chronic inflammatory conditions including psoriasis and inflammatory bowel diseases, modulating lymphocyte function and promoting Th1 and Th17 cell differentiation.
These T-helper cells further activate pro-inflammatory mediators and transcription factors such as TNFα and IFNγ, driving innate and adaptive immune responses.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.